These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11812200)

  • 1. Role of calcium regulation in pathophysiology model of schizophrenia and possible interventions.
    Yarlagadda A
    Med Hypotheses; 2002 Feb; 58(2):182-6. PubMed ID: 11812200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational models of schizophrenia and dopamine modulation in the prefrontal cortex.
    Rolls ET; Loh M; Deco G; Winterer G
    Nat Rev Neurosci; 2008 Sep; 9(9):696-709. PubMed ID: 18714326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiologically based treatment interventions in schizophrenia.
    Lewis DA; Gonzalez-Burgos G
    Nat Med; 2006 Sep; 12(9):1016-22. PubMed ID: 16960576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance.
    Lafargue T; Brasic J
    Med Hypotheses; 2000 Oct; 55(4):314-8. PubMed ID: 11000059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.
    Domino EF; Mirzoyan D; Tsukada H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):801-11. PubMed ID: 15363604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
    du Bois TM; Huang XF
    Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in schizophrenia.
    Thaker GK; Carpenter WT
    Nat Med; 2001 Jun; 7(6):667-71. PubMed ID: 11385502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity.
    Scott L; Aperia A
    Neuroscience; 2009 Jan; 158(1):62-6. PubMed ID: 19000746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of N-methyl-D-aspartate receptors and nitric oxide in cochlear dopamine release.
    Halmos G; Horváth T; Polony G; Fekete A; Kittel A; Vizi ES; van der Laan BF; Zelles T; Lendvai B
    Neuroscience; 2008 Jun; 154(2):796-803. PubMed ID: 18462886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-nMDA receptor encephalitis--clinical manifestations and pathophysiology].
    Iizuka T; Sakai F
    Brain Nerve; 2008 Sep; 60(9):1047-60. PubMed ID: 18807939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
    Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M
    Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postnatal blockade of N-methyl-D-aspartate receptors on rat behavior: a search for a new developmental model of schizophrenia.
    Wedzony K; Fijal K; Mackowiak M; Chocyk A; Zajaczkowski W
    Neuroscience; 2008 Jun; 153(4):1370-9. PubMed ID: 18434025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
    Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
    Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.